TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A study of human brain tissue and experiments in mice link reduced NRF2 activity in oligodendrocytes—the cells that maintain myelin around nerve fibers—to abnormalities associated with faster cognitive decline. The findings suggest a possible treatment target, but do not show that NRF2-targeting drugs prevent decline in older adults.
Researchers from the University of Edinburgh and the UK Dementia Research Institute have linked reduced activity of a protective protein in myelin-producing brain cells with nerve-fiber damage and faster cognitive decline in older age. Their study, published in Nature Medicine, combines findings from human brain tissue and mouse experiments; it points to a possible biological target, but does not establish a treatment for age-related decline.
The researchers examined data from the Lothian Birth Cohort 1936, whose members have had cognitive abilities tracked from childhood into old age. Of 1,091 people enrolled, 866 completed further testing after age 70. Assessments between ages 70 and 82 measured memory, information-processing speed and spatial reasoning. Most participants experienced some decline, but the pace differed among individuals.
In post-mortem brain tissue from a subset of participants, greater decline was associated with fewer large nerve fibers and abnormal accumulations of myelin, the insulating material that helps signals travel along nerve fibers. The researchers reported that these tissue changes tracked the rate of decline, rather than a person’s cognitive test performance at one particular age. The association does not by itself show that the tissue changes caused the decline.
The team focused on oligodendrocytes, the cells that produce and maintain myelin. People with more severe decline had lower levels of NRF2 in these cells. In mice, selectively reducing NRF2 in oligodendrocytes led to excess myelin, loss of large nerve fibers and less improvement in cognitive performance as the animals aged. The experiments support a possible causal role in mice, but cannot establish the same mechanism or effect in people.
A Possible Target in Myelin Cells
The findings suggest that cells usually understood as support for nerve fibers may become dysfunctional with age, and that this dysfunction could be part of the process associated with declining memory and thinking skills. That shifts attention beyond damage to nerve cells themselves toward the supporting cells and myelin that help them function.
NRF2 is a potential research lead because medicines that affect this pathway are already used for other neurological conditions, including multiple sclerosis. The study does not show that these drugs are safe or effective for age-related cognitive decline, nor that they reverse the brain-tissue changes. Any treatment use would require further evidence, including studies specifically involving older adults.
Products Worth Considering
Fitbit Sense 2 Health and Fitness Smartwatch, Shadow Grey/Graphite
BowFlex Results Series SelectTech Adjustable Dumbbells, Pair
Blueair Blue Pure 311i Max Smart Air Purifier
As an affiliate, we earn on qualifying purchases.
From Cohort Records to Mouse Tests
The cohort’s long-running records gave researchers a way to compare cognitive changes over many years with brain tissue collected after participants died. This allowed the team to investigate whether biological features were associated with how quickly abilities changed, rather than relying only on a single late-life test. The tissue analysis involved only a subset of the cohort, so it is not a complete picture of every participant’s brain.
The mouse experiments addressed a different question: whether lowering NRF2 in oligodendrocytes could produce changes resembling those seen in human tissue. The reported results included excess myelin and fewer large nerve fibers, alongside a weaker improvement in cognitive performance with age. Together, the human association and animal experiments provide complementary evidence, but they are not equivalent to demonstrating a cause of cognitive decline in people.
“As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.”
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
Human Treatment Evidence Is Missing
The study does not establish that reduced NRF2 activity is the cause of cognitive decline in people, or that changing the pathway would prevent or slow it. Human tissue findings are associations, while the intervention experiments were conducted in mice. It is also unclear whether abnormalities in myelin and nerve fibers precede cognitive changes, develop alongside them or result partly from other age-related processes.
The source material does not specify how many post-mortem samples were analyzed or provide effect sizes for the reported associations and mouse outcomes. It also does not report a clinical trial of NRF2-targeting drugs for age-related decline. The possibility of adapting existing medicines remains a research prospect, not a treatment recommendation.
Testing NRF2-Based Approaches
Further studies will need to establish how NRF2 activity changes in human oligodendrocytes over time and whether those changes help predict cognitive outcomes. Researchers would also need to test whether altering the pathway can protect nerve fibers without causing harmful effects, first in suitable preclinical work and then in carefully designed human studies.
Although medicines affecting NRF2 are already used for other conditions, their effects in those settings do not establish benefit for older adults with cognitive decline. The next milestone is evidence that a treatment aimed at this pathway can safely change relevant brain processes and improve meaningful outcomes in people. Until then, the study identifies a potential therapeutic target, not a proven intervention.
Key Questions
What brain cells did the study investigate?
It focused on oligodendrocytes, cells that produce and maintain myelin, the insulating coating around nerve fibers.
What is NRF2?
NRF2 is a protein that regulates genes involved in cellular defenses and normal function. The study found lower NRF2 levels in oligodendrocytes in people with more severe cognitive decline.
Did the study prove that these cells cause cognitive decline in people?
No. The human findings show associations in brain tissue. Experiments that reduced NRF2 and produced related changes were conducted in mice, so the results do not prove the same causal process in people.
The research raises that possibility because some medicines used for other neurological conditions act on the NRF2 pathway. This study did not test those medicines as a treatment for age-related decline or show that they work for that purpose.
Source: rss
